VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$31.74
Market Cap
$3.70B
52W High
$42.79
52W Low
$27.16
ADV30
2,752,576
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
| Jun 2025 | 0 | — | -74,574,000 | -65,561,000 | 827,851,000 | 33,880,000 | 32,390,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-340,330,000
Investing CF
$332,332,000
Financing CF
$88,167,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,005,871,000
Inventory
—
Receivables
—
ST Investments
$484,848,000
EBIT TTM
$-501,998,000
Pretax Income TTM
$-472,335,000
Interest Exp TTM
—
Analysts
18
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | — | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | — | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | — | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | — | -48,397,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.45
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LEGN | Legend Biotech Corp | $3.59B | $18.55 | — |
| OGN | Organon & Co. | $3.56B | $13.55 | — |
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | $31.49 | — |
| RCUS | Arcus Biosciences, Inc. | $3.55B | $28.19 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.92B | $54.81 | — |
News headlines (Yahoo Finance, 1h cache)
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
2026-07-30 22:50 · Yahoo
VKTX Launches $500M Shelf After Full Enrollment Of Phase 3 Obesity Drug Study – Retail Bets On ‘Exceptionally Great Data’
2026-07-30 17:00 · Yahoo
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
2026-07-30 16:35 · Yahoo
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
2026-07-30 07:22 · Yahoo
Viking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline ...
2026-07-30 05:03 · Yahoo
Viking Therapeutics Q2 Earnings Call Highlights
2026-07-30 01:04 · Yahoo
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress
2026-07-29 23:58 · Yahoo
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-29 20:05 · Yahoo
3 Biotech Stocks With Massive Upside to Buy Before August Starts
2026-07-29 12:00 · Yahoo
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case
2026-07-28 21:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.